Posted by Michael Wonder on 15 Oct 2024
The US FDA grants fast track designation to Coherent Biopharma’s CBP-1008
10 October 2024 - Coherent Biopharma announced that the US FDA has granted fast track designation to CBP-1008 for injection (CBP-1008) for the treatment of platinum-resistant ovarian clear cell carcinoma.
CBP-1008 is a first in class bi-specific ligand drug conjugate developed using Coherent’s proprietary Bi-XDC technology platform.
